Cyclerion Therapeutics (NASDAQ:CYCN) Announces Quarterly Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) announced its earnings results on Tuesday. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44, Zacks reports. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 58.21%.

Cyclerion Therapeutics Trading Up 0.3%

Shares of Cyclerion Therapeutics stock opened at $3.14 on Thursday. The business has a 50-day moving average price of $2.63 and a two-hundred day moving average price of $1.89. Cyclerion Therapeutics has a 1-year low of $1.03 and a 1-year high of $8.48. The company has a market cap of $13.60 million, a P/E ratio of -2.31 and a beta of 1.80.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. Institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.